SQZ vs. FRTX, KRBP, NSTGQ, PALI, TCBP, TCON, GMDAQ, ELOX, FNCH, and WINT
Should you be buying SQZ Biotechnologies stock or one of its competitors? The main competitors of SQZ Biotechnologies include Fresh Tracks Therapeutics (FRTX), Kiromic BioPharma (KRBP), NanoString Technologies (NSTGQ), Palisade Bio (PALI), TC Biopharm (TCBP), TRACON Pharmaceuticals (TCON), Gamida Cell (GMDAQ), Eloxx Pharmaceuticals (ELOX), Finch Therapeutics Group (FNCH), and Windtree Therapeutics (WINT). These companies are all part of the "biological products, except diagnostic" industry.
SQZ Biotechnologies (NYSE:SQZ) and Fresh Tracks Therapeutics (NASDAQ:FRTX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, risk, community ranking, analyst recommendations, dividends, institutional ownership, valuation, earnings and profitability.
38.5% of SQZ Biotechnologies shares are owned by institutional investors. Comparatively, 25.0% of Fresh Tracks Therapeutics shares are owned by institutional investors. 16.0% of SQZ Biotechnologies shares are owned by company insiders. Comparatively, 0.2% of Fresh Tracks Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Fresh Tracks Therapeutics has lower revenue, but higher earnings than SQZ Biotechnologies. Fresh Tracks Therapeutics is trading at a lower price-to-earnings ratio than SQZ Biotechnologies, indicating that it is currently the more affordable of the two stocks.
Fresh Tracks Therapeutics has a net margin of -91.29% compared to SQZ Biotechnologies' net margin of -369.96%. Fresh Tracks Therapeutics' return on equity of -60.83% beat SQZ Biotechnologies' return on equity.
SQZ Biotechnologies received 10 more outperform votes than Fresh Tracks Therapeutics when rated by MarketBeat users. Likewise, 66.67% of users gave SQZ Biotechnologies an outperform vote while only 0.00% of users gave Fresh Tracks Therapeutics an outperform vote.
In the previous week, Fresh Tracks Therapeutics had 1 more articles in the media than SQZ Biotechnologies. MarketBeat recorded 1 mentions for Fresh Tracks Therapeutics and 0 mentions for SQZ Biotechnologies. Fresh Tracks Therapeutics' average media sentiment score of 0.71 beat SQZ Biotechnologies' score of 0.00 indicating that Fresh Tracks Therapeutics is being referred to more favorably in the news media.
SQZ Biotechnologies has a beta of 2.34, indicating that its share price is 134% more volatile than the S&P 500. Comparatively, Fresh Tracks Therapeutics has a beta of 0.38, indicating that its share price is 62% less volatile than the S&P 500.
Summary
Fresh Tracks Therapeutics beats SQZ Biotechnologies on 8 of the 15 factors compared between the two stocks.
Get SQZ Biotechnologies News Delivered to You Automatically
Sign up to receive the latest news and ratings for SQZ and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SQZ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
SQZ Biotechnologies Competitors List
Related Companies and Tools
